Home/Filings/4/0000905718-21-001618
4//SEC Filing

Abingworth LLP 4

Accession 0000905718-21-001618

CIK 0001828522other

Filed

Dec 16, 7:00 PM ET

Accepted

Dec 17, 4:30 PM ET

Size

7.7 KB

Accession

0000905718-21-001618

Insider Transaction Report

Form 4
Period: 2021-10-06
Transactions
  • Award

    Stock Option (right to buy)

    2021-10-06+40,00040,000 total(indirect: See Footnotes)
    Exercise: $11.36Exp: 2031-10-05Common Stock (40,000 underlying)
Footnotes (3)
  • [F1]Abingworth Bioventures VI GP LP ("Abingworth GP") serves as the general partner of Abingworth Bioventures VI, LP ("ABV VI"). Abingworth General Partner VI LLP serves as the general partner of Abingworth GP. ABV VI (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VI LLP) has delegated to the Reporting Person all investment and dispositive power over the securities held by ABV VI.
  • [F2]The option (the "Option") was granted to Brian Gallagher ("Gallagher"), a director of the Issuer and a member of the investment committee of ABV VI (the "Investment Committee") which approves investment and voting decisions by majority vote. No individual member of the Investment Committee has the sole control or voting power over the securities held by ABV VI. The Option will vest in substantially equal monthly installments over three years, commencing on August 25, 2021, subject to the Gallagher's continued service with the Issuer through each vesting date. Under an agreement between Gallagher and the Reporting Person, Gallagher is deemed to hold the Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV VI, and must exercise the Option solely upon the direction of the Reporting Person.
  • [F3]ABV VI may be deemed the indirect beneficial owner of the Option, and Gallagher may be deemed the indirect beneficial owner of the Option through his indirect interest in ABV VI. Each of ABV VI, Abingworth GP, Abingworth General Partner VI LLP, Gallagher, the Reporting Person and each member of the Investment Committee disclaims beneficial ownership of the Option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Issuer

eFFECTOR Therapeutics, Inc.

CIK 0001828522

Entity typeother
IncorporatedUnited Kingdom

Related Parties

1
  • filerCIK 0001397144

Filing Metadata

Form type
4
Filed
Dec 16, 7:00 PM ET
Accepted
Dec 17, 4:30 PM ET
Size
7.7 KB